105827-74-5

Basic information

• Product Name: 5-(BROMOMETHYL)-2-FLUOROPYRIDINE
• Synonyms: 5-(BROMOMETHYL)-2-FLUOROPYRIDINE;5-(BroMoMethyl)-2-fluorop...
• CAS NO: 105827-74-5
• Molecular Formula: C₆H₅BrFN
• Molecular Weight: 190.02
• Mol File: 105827-74-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 5-(BROMOMETHYL)-2-FLUOROPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(BROMOMETHYL)-2-FLUOROPYRIDINE(105827-74-5)
• EPA Substance Registry System: 5-(BROMOMETHYL)-2-FLUOROPYRIDINE(105827-74-5)

Safety Data

• Hazardous Substances Data: 105827-74-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-(BROMOMETHYL)-2-FLUOROPYRIDINE is used as a reagent for the preparation of N-Benzylisatinsulfonamides, which are potent inhibitors of caspase-3. Caspase-3 is a crucial enzyme involved in the execution phase of apoptosis, or programmed cell death. By inhibiting caspase-3, N-Benzylisatinsulfonamides can potentially be used in the development of treatments for various diseases and conditions where apoptosis plays a significant role, such as cancer, neurodegenerative disorders, and autoimmune diseases.

Upstream product

• 1603-41-4 (5-methyl-pyridin-2-yl)amine 
• 2369-19-9 2-fluoro-5-methylpyridine 

Downstream Products

• 1253569-19-5 tert-butyl 4-((6-(6-methoxypyridin-3-ylamino)-5-(4-methyl-6-(methylthio)-1,3,5-triazin-2-yl)pyridin-3-yl)methyl)piperazine-1-carboxylate 
• 1298135-05-3 N,N-bis(4-methoxybenzyl)-4-(2-(6-methoxypyridin-3-ylamino)-5-(piperazin-1-ylmethyl)pyridin-3-yl)-6-methyl-1,3,5-triazin-2-amine 
• 1253569-13-9 tert-butyl 4-((5-(4-(bis(4-methoxybenzyl)amino)-6-methyl-1,3,5-triazin-2-yl)-6-fluoropyridin-3-yl)methyl)piperazine-1-carboxylate 
• 1253569-01-5 5-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-2-fluoropyridin-3-ylboronic acid 
• 915408-48-9 N-(7-((6-fluoropyridin-3-yl)methyl)-9-(4-methoxybenzyloxy)-8-oxo-7,8-dihydro-6H-pyrrolo[3,4-g]quinolin-5-yl)-N-methylmethanesulfonamide 
• 205744-17-8 2-fluoropyridin-5-ylmethylamine 

Relevant articles and documents

Synthesis and herbicidal activity of 2-cyano-3-(2-fluoro-5-pyridyl) methylaminoacrylates

A series of 2-cyano-3-(2-fluoro-5-pyridyl)methylaminoacrylates were synthesized as herbicidal inhibitors of photosystem II (PSII) electron transport. 2-Fluoro-5-pyridinemethylamine was prepared from 2-amino-5- methylpyridine, subsequent reaction with 2-cyano-3,3-dimethylthioacrylates or 2-cyano-3-methoxyacrylates to yield these title compounds. All of these compounds were confirmed by 1H NMR, IR, mass spectrum and elemental analyses. Their herbicidal activities were evaluated. All of the title compounds showed excellent herbicidal activities to amaranth pigweed and rape in post-emergence treatment. At the rate of 150 g/ha, one compound exhibited similar activity to Cl-analogue. The replacement of chlorine by fluorine group showed the same herbicidal activity.

In vitro and in vivo evaluation of fluorinated indanone derivatives as potential positron emission tomography agents for the imaging of monoamine oxidase B in the brain

Monoamine oxidases (MAOs) play a key role in the metabolism of major monoamine neurotransmitters. In particular, the upregulation of MAO-B in Parkinson's disease, Alzheimer's disease and cancer augmented the development of selective MAO-B inhibitors for d

MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).

PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS

The present invention provides a selection of compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activ

Mesoionic pyrido[1,2-a]pyrimidinones: Discovery of triflumezopyrim as a potent hopper insecticide1

A novel class of mesoionic pyrido[1,2-a]pyrimidinones has been discovered with exceptional insecticidal activity controlling a number of insect species. In this communication, we report the part of the optimization program which led to the discovery of triflumezopyrim as a highly potent insecticide controlling various hopper species. Our efforts in discovery, synthesis, structure-activity relationship elucidation, and biological activity evaluation are also presented.

Modular Route to Azaindanes

A convergent radical based route to azaindanes is described, relying on the degenerative addition transfer of various substituted S-(pyridylmethyl)-O-ethyl dithiocarbonates (xanthates) to functional alkenes followed by radical cyclization onto the pyridine ring activated by protonation with trifluoroacetic acid. In one case, a richly decorated cyclohepta[b]pyridine could be assembled swiftly by allowing the first adduct to N-phenylmaleimide to undergo addition to N-allylphthalimide prior to cyclization.

N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS,

The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicat

LABELLED CHROMONE DERIVATIVES

The present invention relates to compounds having selective binding for MAO-B as compared with MAO-A. The invention also provides radioactive versions of these compounds, and precursor compounds for the synthesis of these radioactive compounds. The radioa

6-SUBSTITUTED-3H-1,3-BENZOTHIAZOL-2-ONE COMPOUNDS AS TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONISTS

A TARP ?8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N; A is; and R1 is as defined herein; its pharmaceutically acceptable salts, uses, and methods for its preparation are described.

HETEROCYCLIC DERIVATES

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B,W, X, Y and Z are as defined herein.